01 January 1996
Effect of fluvastation on serum lipids in patients with essential hypertension
Judit Kaposci, Csaba Farsang, Gyula Pados, Katalin Detki, Zoltan Jarai, Janos Hollo, Zsuzsanna SebestyenMed Sci Monit 1996; 2(1): CR37-40 :: ID: 499518
Abstract
Background: to assess the efficacy and safety of fluvastatin in the treatment of hypercholesterolaemia in hypertensive patients (WHO I-II).
Material/Methods: An 8 week low-lipid diet was started if the fasting total cholesterol (TC) level was equal to or higher than 6.5 mM and the triglyceride (TG) level was lower than 4.6 mM. After the dietary period fluvastatin treatment was started, (20 mg daily) if the LDL-C level was >4.1 mM. Blood pressure, heart rate, as well as TC, HDL-C (HDL2-C, HDL3-C), apo A1, apo B and TG were measured at 4, 8 and 12 weeks of treatment. The daily dose of fluvastatin was increased to 40 mg, if a satisfactory lowering of LDL-C (3.5 mM) was not obtained after 4 weeks of treatment. The number of patients included in the study was 49, mean age 57.0±10.7 years (X&plusm;SD), the blood pressure 142 ±16/85 ±11 mmHg (systolic/diastolic respectively). The antihypertensive treatment remained unchanged.
Results: Thirty-six patients completed the study (6 patients were withdrawn because of lack of compliance, 7 patients were withdrawn at the end of the dietary period, because of the normalisation of lipid levels). Fluvastatin significantly reduced the TC level (from 7.22±0.88 mM to 5.99±0.98 mM), LDL-C (from 5.13±0.78 mM to 3.95±0.88 mM) and Apo B (from 0.97±0.21 mM to 0.85±0.15 mM), but did not influence the levels of HDL-C, Apo A1 and TG. The diastolic blood pressure decreased significantly by the end of the dietary period. After the administration of fluvastatin, the systolic blood pressure decreased significantly. Only minor side effects were observed.
Conclusions: Fluvastatin proved to be an effective and well tolerated drug in the treatment of hypercholesterolaemia in hypertensive patients.
Keywords: essential hypertension, fluvastatin, hypercholesterolaemia
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952